Program Snapshot

The Common Fund’s Regulatory Science program was a collaborative effort to accelerate the development and use of new tools, standards and approaches to efficiently develop medical products and to more effectively evaluate medical product safety, efficacy and quality. A major focus of the program was the development of cutting edge microphysiological systems (MPS), or “tissue chips”, to more accurately predict drug safety and efficacy in humans.

This page last reviewed on January 18, 2018